CERo Therapeutics Announces Activation of the University of California, Davis as a Clinical Trial Site for the Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies
CERo Therapeutics announced the University of California, Davis has been activated as a clinical trial site for CERTAIN-T, its Phase 1/1b study of CER-1236 in hematologic malignancies. UC Davis also serves as the primary manufacturing site for CER-1236, so the site combines patient enrollment with cell manufacturing to shorten the time between manufacturing and infusion.
Key figures
- Drug Name
- CER-1236
- Phase Of Trial
- Phase 1/1b
- Trial name
- CERTAIN-T
- Patients treated to date
- 6
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.